Tumor suppressive role of the antimicrobial lectin REG3A targeting the O-GlcNAc glycosylation pathway.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 08 01 2024
accepted: 06 06 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: aheadofprint

Résumé

Antimicrobial proteins of the REG3 family provide a first line of protection against infections and transformed cells. Their expression is inducible by inflammation, which makes their role in cancer biology less clear, since an immune- inflammatory context may preexist or coexist with cancer, as occurs in hepatocellular carcinoma (HCC). The aim of this study is to clarify the role of REG3A in liver carcinogenesis and to determine whether carbohydrate-binding functions are involved. This study provides evidence of the suppressive role of REG3A in HCC by reducing O-GlcNAcylation in two mouse models of HCC, in vitro cell studies, and in clinical samples. REG3A expression in hepatocytes significantly reduces global O- GlcNAcylation and O-GlcNAcylation of c-MYC in preneoplastic and tumor livers and markedly inhibits HCC development in REG3A-c-MYC double transgenic mice and in mice exposed to diethylnitrosamine (DEN). REG3A modifies O-GlcNAcylation without altering the expression or activity of OGT, OGA, or GFAT. Reduced O-GlcNAcylation was consistent with decreased levels of UDP-GlcNAc in pre-cancerous and cancerous livers. This effect is linked to the ability of REG3A to bind Glc and Glc-6P, suggested by a REG3A mutant unable to bind Glc and Glc- 6P and alter O-GlcNAcylation. Importantly, cirrhotic patients with high hepatic REG3A expression had lower levels of O-GlcNAcylation and longer cancer-free survival than REG3A- negative cirrhotic livers. REG3A helps fight liver cancer by reducing O-GlcNAcylation. This study suggests a new paradigm for the regulation of O-GlcNAc signalling in cancer-related pathways through interactions with the carbohydrate-binding function of REG3A.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Antimicrobial proteins of the REG3 family provide a first line of protection against infections and transformed cells. Their expression is inducible by inflammation, which makes their role in cancer biology less clear, since an immune- inflammatory context may preexist or coexist with cancer, as occurs in hepatocellular carcinoma (HCC). The aim of this study is to clarify the role of REG3A in liver carcinogenesis and to determine whether carbohydrate-binding functions are involved.
APPROACH AND RESULTS RESULTS
This study provides evidence of the suppressive role of REG3A in HCC by reducing O-GlcNAcylation in two mouse models of HCC, in vitro cell studies, and in clinical samples. REG3A expression in hepatocytes significantly reduces global O- GlcNAcylation and O-GlcNAcylation of c-MYC in preneoplastic and tumor livers and markedly inhibits HCC development in REG3A-c-MYC double transgenic mice and in mice exposed to diethylnitrosamine (DEN). REG3A modifies O-GlcNAcylation without altering the expression or activity of OGT, OGA, or GFAT. Reduced O-GlcNAcylation was consistent with decreased levels of UDP-GlcNAc in pre-cancerous and cancerous livers. This effect is linked to the ability of REG3A to bind Glc and Glc-6P, suggested by a REG3A mutant unable to bind Glc and Glc- 6P and alter O-GlcNAcylation. Importantly, cirrhotic patients with high hepatic REG3A expression had lower levels of O-GlcNAcylation and longer cancer-free survival than REG3A- negative cirrhotic livers.
CONCLUSION CONCLUSIONS
REG3A helps fight liver cancer by reducing O-GlcNAcylation. This study suggests a new paradigm for the regulation of O-GlcNAc signalling in cancer-related pathways through interactions with the carbohydrate-binding function of REG3A.

Identifiants

pubmed: 38975812
doi: 10.1097/HEP.0000000000000993
pii: 01515467-990000000-00943
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.

Auteurs

Nicolas Moniaux (N)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Nicolas Geoffre (N)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Marion Darnaud (M)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Alice Deshayes (A)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Alexandre Dos Santos (A)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Sylvie Job (S)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Claire Lacoste (C)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Tung-Son Nguyen (TS)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Mélanie Friedel-Arboleas (M)

Université Grenoble Alpes, CNRS, CEA, IBS, 38185 Grenoble, France.

Catherine Guettier (C)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.
Assistance Publique-Hôpitaux de Paris (AP-HP). Université Paris-Saclay, Hôpital Bicêtre, Laboratoire Anatomie Pathologique, Le Kremlin Bicêtre 94270, France.

Janne Purhonen (J)

Folkhälsan Research Center, Helsinki, Finland.
Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Jukka Kallijärvi (J)

Folkhälsan Research Center, Helsinki, Finland.
Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Gilles Amouyal (G)

Alfact Innovation Paris 75001, France.

Paul Amouyal (P)

Alfact Innovation Paris 75001, France.

Christian Bréchot (C)

USF Health, University of South Florida, Tampa, USA.

Romain Vives (R)

Université Grenoble Alpes, CNRS, CEA, IBS, 38185 Grenoble, France.

Marie Annick Buendia (MA)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.

Tarik Issad (T)

Université de Paris, Institut Cochin, CNRS, INSERM, 75014 Paris, France.

Jamila Faivre (J)

INSERM, U1193, Paul-Brousse University Hospital, Hepatobiliary Center, Villejuif 94800, France.
Université Paris-Saclay, Faculté de Médecine Le Kremlin-Bicêtre 94270, France.
Assistance Publique-Hôpitaux de Paris (AP-HP). Université Paris-Saclay, Medical-University Department (DMU) Biology Genetics, Paul-Brousse Hospital, Villejuif 94800, France.

Classifications MeSH